{"title":"乳腺癌女性患者接受低分流结节区域放疗后的长期淋巴水肿率:2期临床试验--\"HeNRIetta\"","authors":"","doi":"10.1016/j.ijrobp.2024.07.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose/Objective(s)</h3><div>Moderate hypofractionation in the management of localized breast cancer is considered standard of care. Data suggests its use in the setting of regional nodal irradiation (RNI) yields equivalent oncologic and cosmetic outcomes but has not yet achieved universal acceptance into practice. The risk of lymphedema (LA) has not been the focus of study in this setting and therefore, we sought to evaluate the risk and establish the rate of moderate or marked LA for patients treated with hypofractionated RNI utilizing an established and commonly used hypofractionation treatment scheme with standardized treatment volumes for patients with node-positive breast cancer.</div></div><div><h3>Materials/Methods</h3><div>Women with node positive breast cancer who underwent definitive surgical resection were eligible for enrollment. Breast surgery may have been lumpectomy (Lp), mastectomy without reconstruction (M-R), or mastectomy with reconstruction (M+R). Nodal staging by sentinel lymph node (SLN) or by axillary lymph node (ALN) dissection were included. Patients could undergo neoadjuvant or adjuvant chemotherapy at the discretion of the treating medical oncologist. Breast and RNI was administered to 42.56 Gy in 16 daily fractions. The dissected axilla was excluded as a target volume in patients who underwent ALN dissection. Primary endpoint was rate of LA at 3 years following RNI for two cohorts, SLN (cohort A) and ALN (cohort B). Lymphedema was defined as ≥ 10% increase in arm circumference over baseline circumference as compared to the contralateral arm measured every 6 months for the first 3 years. Per protocol-defined to declare moderate hypofractionation non-inferior to recent historical controls cohorts A and B rate of lymphedema were estimated to be 6% and 10% respectively, a non-inferiority margin of +/- 7% was used. Secondary objectives included 5-year oncologic outcomes, grade 3 or higher toxicities, cosmesis and patient reported outcomes.</div></div><div><h3>Results</h3><div>Between September 2015 and July 2021, a total of 134 women were enrolled, 84 underwent SLN only and 50 completed ALN dissection. Mean age was 58.1 years for cohort A and 62.5 years for cohort B. Lp, M+R, and M-R was performed in 58.2%, 19.4, and 30% respectively. LA was observed in 11 patients (13.1%) with SLN only (<em>P</em> = 0.5897) and 9 patients (18%) who underwent ALN dissection (<em>P</em> = 0.65971). Only 2 patients developed grade 2 LA (limiting instrumental activities of daily living) and no grade 3 (limiting self-care activities of daily living) was observed. At 36 month follow up 85.5% in the lumpectomy group and 75.9% in the mastectomy with reconstruction group had excellent or good cosmesis.</div></div><div><h3>Conclusion</h3><div>Moderate hypofractionation did not meet the criteria defined by the protocol for non-inferiority. However, the absolute rates of LA remain low and predominantly grade 1. Cosmetic outcomes in this advanced disease group of patients are favorable. This data does not appear to support the argument that the risk of LA is a reason to avoid moderate hypofractionated regional nodal irradiation.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long Term Rates of Lymphedema in Hypofractionated Nodal Regional Irradiation for Women with Breast Cancer: A Phase 2 Clinical Trial – “HeNRIetta”\",\"authors\":\"\",\"doi\":\"10.1016/j.ijrobp.2024.07.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose/Objective(s)</h3><div>Moderate hypofractionation in the management of localized breast cancer is considered standard of care. Data suggests its use in the setting of regional nodal irradiation (RNI) yields equivalent oncologic and cosmetic outcomes but has not yet achieved universal acceptance into practice. The risk of lymphedema (LA) has not been the focus of study in this setting and therefore, we sought to evaluate the risk and establish the rate of moderate or marked LA for patients treated with hypofractionated RNI utilizing an established and commonly used hypofractionation treatment scheme with standardized treatment volumes for patients with node-positive breast cancer.</div></div><div><h3>Materials/Methods</h3><div>Women with node positive breast cancer who underwent definitive surgical resection were eligible for enrollment. Breast surgery may have been lumpectomy (Lp), mastectomy without reconstruction (M-R), or mastectomy with reconstruction (M+R). Nodal staging by sentinel lymph node (SLN) or by axillary lymph node (ALN) dissection were included. Patients could undergo neoadjuvant or adjuvant chemotherapy at the discretion of the treating medical oncologist. Breast and RNI was administered to 42.56 Gy in 16 daily fractions. The dissected axilla was excluded as a target volume in patients who underwent ALN dissection. Primary endpoint was rate of LA at 3 years following RNI for two cohorts, SLN (cohort A) and ALN (cohort B). Lymphedema was defined as ≥ 10% increase in arm circumference over baseline circumference as compared to the contralateral arm measured every 6 months for the first 3 years. Per protocol-defined to declare moderate hypofractionation non-inferior to recent historical controls cohorts A and B rate of lymphedema were estimated to be 6% and 10% respectively, a non-inferiority margin of +/- 7% was used. Secondary objectives included 5-year oncologic outcomes, grade 3 or higher toxicities, cosmesis and patient reported outcomes.</div></div><div><h3>Results</h3><div>Between September 2015 and July 2021, a total of 134 women were enrolled, 84 underwent SLN only and 50 completed ALN dissection. Mean age was 58.1 years for cohort A and 62.5 years for cohort B. Lp, M+R, and M-R was performed in 58.2%, 19.4, and 30% respectively. LA was observed in 11 patients (13.1%) with SLN only (<em>P</em> = 0.5897) and 9 patients (18%) who underwent ALN dissection (<em>P</em> = 0.65971). Only 2 patients developed grade 2 LA (limiting instrumental activities of daily living) and no grade 3 (limiting self-care activities of daily living) was observed. At 36 month follow up 85.5% in the lumpectomy group and 75.9% in the mastectomy with reconstruction group had excellent or good cosmesis.</div></div><div><h3>Conclusion</h3><div>Moderate hypofractionation did not meet the criteria defined by the protocol for non-inferiority. However, the absolute rates of LA remain low and predominantly grade 1. Cosmetic outcomes in this advanced disease group of patients are favorable. This data does not appear to support the argument that the risk of LA is a reason to avoid moderate hypofractionated regional nodal irradiation.</div></div>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0360301624007703\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0360301624007703","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Long Term Rates of Lymphedema in Hypofractionated Nodal Regional Irradiation for Women with Breast Cancer: A Phase 2 Clinical Trial – “HeNRIetta”
Purpose/Objective(s)
Moderate hypofractionation in the management of localized breast cancer is considered standard of care. Data suggests its use in the setting of regional nodal irradiation (RNI) yields equivalent oncologic and cosmetic outcomes but has not yet achieved universal acceptance into practice. The risk of lymphedema (LA) has not been the focus of study in this setting and therefore, we sought to evaluate the risk and establish the rate of moderate or marked LA for patients treated with hypofractionated RNI utilizing an established and commonly used hypofractionation treatment scheme with standardized treatment volumes for patients with node-positive breast cancer.
Materials/Methods
Women with node positive breast cancer who underwent definitive surgical resection were eligible for enrollment. Breast surgery may have been lumpectomy (Lp), mastectomy without reconstruction (M-R), or mastectomy with reconstruction (M+R). Nodal staging by sentinel lymph node (SLN) or by axillary lymph node (ALN) dissection were included. Patients could undergo neoadjuvant or adjuvant chemotherapy at the discretion of the treating medical oncologist. Breast and RNI was administered to 42.56 Gy in 16 daily fractions. The dissected axilla was excluded as a target volume in patients who underwent ALN dissection. Primary endpoint was rate of LA at 3 years following RNI for two cohorts, SLN (cohort A) and ALN (cohort B). Lymphedema was defined as ≥ 10% increase in arm circumference over baseline circumference as compared to the contralateral arm measured every 6 months for the first 3 years. Per protocol-defined to declare moderate hypofractionation non-inferior to recent historical controls cohorts A and B rate of lymphedema were estimated to be 6% and 10% respectively, a non-inferiority margin of +/- 7% was used. Secondary objectives included 5-year oncologic outcomes, grade 3 or higher toxicities, cosmesis and patient reported outcomes.
Results
Between September 2015 and July 2021, a total of 134 women were enrolled, 84 underwent SLN only and 50 completed ALN dissection. Mean age was 58.1 years for cohort A and 62.5 years for cohort B. Lp, M+R, and M-R was performed in 58.2%, 19.4, and 30% respectively. LA was observed in 11 patients (13.1%) with SLN only (P = 0.5897) and 9 patients (18%) who underwent ALN dissection (P = 0.65971). Only 2 patients developed grade 2 LA (limiting instrumental activities of daily living) and no grade 3 (limiting self-care activities of daily living) was observed. At 36 month follow up 85.5% in the lumpectomy group and 75.9% in the mastectomy with reconstruction group had excellent or good cosmesis.
Conclusion
Moderate hypofractionation did not meet the criteria defined by the protocol for non-inferiority. However, the absolute rates of LA remain low and predominantly grade 1. Cosmetic outcomes in this advanced disease group of patients are favorable. This data does not appear to support the argument that the risk of LA is a reason to avoid moderate hypofractionated regional nodal irradiation.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.